Skip to main content
Sign In

Flaig Research Lab

Genitourinary Cancer

Flaig Lab Pic
From left to right: Xiaoping Yang, Thomas Flaig, Lih-Jen Su


Genitourinary Cancer Translational Research

Selected Publications

1. Arthur C, Flaig T, Su L, Denney R, Barnes F, Glodé LM. The effect of ultrasonic irradiation on doxorubicin-induced cytotoxicity in three human bladder cancer cell lines. Ultrasonics. 2007; 46(1): 68-73. PMID 17173946

2. Flaig TW, Su Lih-Jen, Agarwal R, Glodé LM. Silibinin synergizes with mitoxantrone to inhibit cell growth via apoptosis in prostate cancer cells. International Journal of Cancer. 2007; 120(9): 2028-33. PMID 17230508

3. Flaig TW, Su L, Uhlik C, Li Y, Raben D, Garcia M, and Bemis L Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU International. 2009; 103(12): 1729-37. PMID 19220256

4. Flaig TW, Glodé M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su L, Yuan L, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M. A Study of High-Dose Oral Silybin-Phytosome Followed by Prostatectomy in Patients with Localized Prostate Cancer. The Prostate. 2010; 70(8): 848-55. PMID 20127732

5. Li Y, Yang X, Su L, Flaig TW. VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cells. Oncology Reports. 2010; 24(4): 1019-28. PMID: 20811684

6. Li Y, Yang X, Su L, Flaig, TW. Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells. Urology. 2011;78(1): 233.e7—233.e13. PMID 21529900 PMC3126899

7. Yang X, Bemis L, Su L-J, Gao D, Flaig TW. miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2. BioResearch Open Access. 2012, 1(2): 55-62. PMID:23514806

8. Yang X, Kessler E, Su, L Thorburn A, Frankel AE, Li Y, La Rosa FG, Shen J, Li C, Varella-Garcia M, Glodé LM, Flaig TW. Diphtheria Toxin–Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer. Clinical Cancer Research. 2012; 19(1): 148-57. PMID:23172881

© The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.